Mode
Text Size
Log in / Sign up
Phase 2 Completed N=51 Treatment

A Study of E7080 in Subjects With Advanced Thyroid Cancer

Source: ClinicalTrials.gov NCT01728623 ↗
Enrolled (actual)
51
Serious AEs
52.9%
Results posted
Aug 2020
Primary outcomePrimary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 100.0; 82.4; 52.9; 2.0 Percentage of participants

Summary

This study is to evaluate the safety, efficacy, and pharmacokinetics of E7080 when orally administered once daily (QD) in subjects with advanced thyroid cancer.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)
100.0; 82.4; 52.9; 2.0; 96.1; 66.7
SECONDARY
Progression-free Survival (PFS)
25.8; 9.2; 7.4
SECONDARY
Overall Survival (OS)
31.8; 12.1; 10.6
SECONDARY
Best Overall Response (BOR)
0; 0; 0; 68.0; 22.2; 23.5
SECONDARY
Objective Response Rate (ORR)
68.0; 22.2; 23.5
SECONDARY
Disease Control Rate (DCR)
100.0; 100.0; 94.1
SECONDARY
Clinical Benefit Rate (CBR)
84.0; 77.8; 70.6

Eligibility Criteria

Inclusion criteria

  • Histologically or clinically diagnosed with thyroid cancer
  • Eastern Cooperative Oncology Group Performance Status (ECOG-PS) 0-2
  • Adequate laboratory values/organ function tests

Exclusion criteria

Participants with following complication or disease history

  • Brain metastasis
  • Systemic severe infection
  • Significant cardiovascular impairment
  • QTc greater than 480 milliseconds
  • Active hemoptysis
  • Bleeding or thrombotic disorders
  • Having greater than 1+ proteinuria on urine dipstick testing will undergo 24 hour urine collection for quantitative assessment of proteinuria
  • Gastrointestinal malabsorption or any other condition in the opinion of the investigator that might affect the absorption of E7080
  • Major surgery within 3 weeks before enrollment
  • With co-existing effusion requiring drainage
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01728623). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search